Angiotensin II and new vessel formation: Aiming for the right oxidative window

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 1, 2008, Pages 4-5

  Velasquez Castano, Juan C ^a   Taylor, W Robert ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; VASCULOTROPIN;

ANGIOGENESIS; CARDIOVASCULAR DISEASE; EDITORIAL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; METABOLIC SYNDROME X; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; WISTAR KYOTO RAT;

ANGIOTENSIN II; ANIMALS; DISEASE MODELS, ANIMAL; ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; OXIDATIVE STRESS; RATS;

EID: 37549012131     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.155978     Document Type: Editorial

References (10)

1. Billinger M, Kloos P, Eberli FR, Windecker S, Meier B, Seiler C. Physiologically assessed coronary collateral flow and adverse cardiac ischemic events: a follow-up study in 403 patients with coronary artery disease. J Am Coll Cardiol. 2002;40:1545-1550.
2. Nathoe HM, Koerselman J, Buskens E, van Dijk D, Stella PR, Plokker TH, Doevendans PA, Grobbee DE, de Jaegere PP. Determinants and prognostic significance of collaterals in patients undergoing coronary revascularization. Am J Cardiol. 2006;98:31-35.
3. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494-501.
4. Epstein SE, Stabile E, Kinnaird T, Lee CW, Clavijo L, Burnett MS. Janus phenomenon: the interrelated tradeoffs inherent in therapies designed to enhance collateral formation and those designed to inhibit atherogenesis. Circulation. 2004;109:2826-2831.
5. Ichiki T. Role of renin angiotensin system in angiogenesis: it is still elusive. Arterioscler Thromb Vas Biol. 2004;24:622-624.
6. Fabre JE, Rivard A, Magner M, Silver M, Isner JM. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation. 1999;99:3043-3049.
7. Silvestre JS, Bergaya S, Tamarat R, Duriez M, Boulanger CM, Levy BI. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res. 2001;89: 678-683.
8. Heil M, Eitenmuller I, Schmitz-Rixen T, Schaper W. Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med. 2006; 10:45-55.
9. Reed R, Kolz C, Potter B, Rocic P. The mechanistic basis for the disparate effects of angiotensin II on coronary collateral growth. Arterioscler Thromb Vas Biol. 2007;27:61-67.
10. Rocic P, Kolz C, Reed R, Potter B, Chilian WM. Optimal reactive oxygen species concentration and p38 MAP kinase are required for coronary collateral growth. Am J Physiol. 2007;292:H2729-HJ2736.